Duchmann, Matthieu
Itzykson, Raphael
Article History
Received: 1 April 2019
Revised: 11 April 2019
Accepted: 15 April 2019
First Online: 24 April 2019
Compliance with ethical standards
:
: MD declares no competing financial interests. RI has received research funding from Janssen, Novartis and Oncoethix (now Merck), honoraria from Sanofi, BMS and Celgene and consulting fees from Novartis, Otsuka Pharma, Jazz Pharmaceuticals, Karyopharm, StemLine Therapeutics and Abbvie.
Free to read: This content has been made available to all.